Brief: FDA Consents Ehave To Proceed Its Clinical Study On Intravenous Ketamine Infusion
15/12/2022 13:40
Dec 15 (Reuters) - Ehave Inc EHVVF.PK :
* FDA GRANTS EHAVE CONSENT TO PROCEED WITH ITS CLINICAL
STUDY ON
INTRAVENOUS KETAMINE INFUSION FOR MAJOR DEPRESSIVE DISORDER
Source text for Eikon: ID:nGNX9ZcTmL
Further company coverage: EHVVF.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ehave
See all newsBrief: Google Partner Novacore Labs and AIBotics Complete Acquisition of Assets
Brief: AIbotics Signs Agreement To Develop UI/UX For Phill Robot, Its AI-Powered Massage Robot
Brief: FDA Consents Ehave To Proceed Its Clinical Study On Intravenous Ketamine Infusion
Brief: Ehave Says Mycotopia Therapies Agrees On Triangular Merger With Ei.Ventures to Form PSLY.com to List on NASDAQ
Brief: Ehave Plans Stock Distribution Mycotopia Therapies Plans To Merge With Ei. Ventures